Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 3/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.37 |
| ▸ | CPT1A | P50416 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | CASP3 | P42574 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040590 | 0.93 | HCRTR1 (0.42) | HCRTR1HCRTR2SMN1; SMN2KCNH2SMO | |
| SCHEMBL10040580 | 0.89 | RAB9A (0.40) | HCRTR1HCRTR2SMN1; SMN2ACKR3KCNH2 | |
| SCHEMBL10040563 | 0.88 | SMN1; SMN2 (0.49) | SMN1; SMN2SMOUSP30 | |
| SCHEMBL10040585 | 0.86 | SMN1; SMN2 (0.44) | SMN1; SMN2ACKR3SMORAB9ANPC1 | |
| SCHEMBL10040581 | 0.85 | ACKR3 (0.41) | HCRTR1HCRTR2SMN1; SMN2ACKR3KCNH2 | |
| SCHEMBL10040570 | 0.84 | FAAH (0.39) | HCRTR1HCRTR2SMN1; SMN2ACKR3KCNH2 | |
| SCHEMBL10040591 | 0.82 | KCNH2 (0.40) | HCRTR1HCRTR2SMN1; SMN2KCNH2SMO | |
| SCHEMBL10040508 | 0.81 | SMN1; SMN2 (0.53) | SMN1; SMN2USP30 | |
| SCHEMBL10070556 | 0.79 | HCRTR1 (0.42) | HCRTR1HCRTR2FAAHCPT1ACASP3 | |
| SCHEMBL12782498 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2SMOFAAHUSP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-8207199-B2 | Azole compound | ASTELLAS PHARMA INC. (JP) | 2012-06-26 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| US-20110118311-A1 | AZOLE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2011-05-19 | — | — | US | disclosed |
| EP-2308869-A1 | AZOLE COMPOUND | Astellas Pharma Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010007966-A1 | AZOLE COMPOUND | アステラス製薬株式会社 (JP) | 2010-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118311-A1 | AZOLE COMPOUND | FAAH, FAAH2, TRPV1 | HCRTR1 314/4885HCRTR2 371/4885SMN1; SMN2 1891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.